Q: How did you become interested in genomic and transcriptomic research?

 

A: My undergraduate degrees are in chemistry and molecular biology, and my graduate work at Caltech focused on building small molecules to site-specifically target DNA. I have spent the last 20 years working in genomics starting with development of microarray technologies for low cost, bioelectronic DNA detection at Clinical Micro Sensors (CMS) in Pasadena, CA. This eSensor platform is the basis of GenMark Diagnostics today. I am a big believer that genomic information should be routinely employed in the management of disease, and I founded DxTerity with the goal of bringing genomics to everyday care. Our DxDirect Genomics Platform and DxCollect Fingerstick Collection Kit enable low cost, from home genomic testing and monitoring.

Q: What was the first DNA test that you developed?

 

A: A multiplex Cystic Fibrosis SNP test on the eSensor platform while at Clinical Micro Sensors.

Q: What are the challenges facing human genomic research today?

 

A: The biggest challenges are completing the clinical studies needed to demonstrate the clinical validity, clinical utility, and economic value of promising genomic tests, as well as obtaining regulatory clearance and reimbursement. Many of the most promising genomic tests are multi-gene panels that rely on a complex algorithm to make a non-obvious medical determination. Large-scale studies are needed to prove value, and the traditional multi-site, KOL-led studies are too expensive and slow. DxTerity’s foray into Direct-to-Patient studies, as well as high-quality, FDA-compliant product development, look to overcome these challenges and enable rapid, cost-effective commercialization of diagnostic tests.

Q: What are the benefits of DxTerity’s Direct-to-Patient platform for genomic research?

 

A: DxTerity provides much needed innovation to genomic research by offering unprecedented access to patient samples. DxTerity’s Direct-to-Patient (D2P) platform uses a single centralized Institutional Review Board (IRB), nationwide digital recruitment of patient cohorts, and “from home” sampling of participants to dramatically lower the resource and financial burden of clinical studies for both the test developer and participant. With our D2P platform, the patient is the site, and sampling and monitoring can be preformed anytime, anywhere, on anyone. This streamlined, integrated approach makes large-scale longitudinal studies economically feasible. By driving down the cost to accessing participants, and collecting samples more frequently from larger cohorts, DxTerity’s D2P platform provides the ability to gain a much higher resolution picture of disease activity and therapy response. Plus, studies can be performed on an accelerated timeframe. Organizations could enroll patients and begin a study in months, and gather data in record time.

Q: Can you give an example of a recent study that the Direct-to-Patient platform was used to collect genomic data?

 

A: The LIFT Study, or Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization, was an observational research study that, utilizing DxTerity’s D2P platform and the DxCollect fingerstick kit, recruited 1,000 participants in less than 6 weeks via online efforts. Participants provided three self-collected fingerstick blood samples using our DxCollect kit and returned them by standard U.S. mail. We had a 97% success rate for determining Interferon High/Low status on the basis of a gene expression signature.

Q: What are the challenges that the field of genomic research will face in the next five years?

 

A: Testing at the genome/transcriptome level is readily available. The next challenge is making it medically available at a reasonable cost, and integrating it in wearables and patient-reported data to enable cost effective, from home monitoring. At the same time, we need to navigate the FDA, insurance providers, and the medical community at large to delineate a reasonable, expedient pathway for the validation and reimbursement of promising tests and patient management offerings. Managed care providers, pharmaceutical companies, and the US government can play key roles by making clinical samples available that can be used to validate the performance of new tests.

Q: You joined CMS shortly after receiving your PhD in chemistry from Caltech. What advice can you give to young scientists considering an industry career?

 

A: There has never been a better time to join the field of genomics research. Advances in genomic technologies and a patient-centric approach to clinical sampling will usher in a new renaissance of large-scale, low-cost clinical studies that advance discovery and innovation in precision medicine and chronic disease monitoring and treatment. Be thorough, thoughtful, and passionate about your work, and remember the “why” behind what you do: the use of genomic profiling for chronic disease monitoring could someday help improve the quality of life for patients living with chronic diseases.

Data Privacy, the Security, And Ownership

The recent Facebook data breach, genetic data sleuthing by the FBI that led to the Golden State Killer, and the soon-to-be-implemented European General Data Protection Regulation (GDPR), has put data privacy and security front and center.

Read More

Q&A with Jason Crites from IBM & Piers Nash from Health2047 Speaking at PMWC 2018 Michigan in June

Q: What need is IBM and Health2047 addressing in the healthcare/life sciences sector?

Jason (IBM): The industry is undergoing a significant transformation as reimbursement shifts from fee-for-service to value-based outcomes in the face of regulatory uncertainty.

Read More

Dr. Francis Collins of NIH at June PMWC Michigan- Launch of Nationwide Participation Enrollment!

This past Sunday—May 6, 2018—the program reached a major milestone with the start of the nationwide participation enrollment! The All of Us Research Program, part of the Precision Medicine Initiative that was famously announced by President Barack Obama at the 2015 State of the Union address, aims to enroll a total of 1 million Americans.

Read More

Meet Dr. Gil Omenn, Director of the University of Michigan Center for Computational Medicine & Bioinformatics on June 6th at PMWC 2018 Michigan

Q: What are the objectives of the Human Proteome Project and what are some of the recent breakthrough discoveries?

The HUPO Human Proteome Project has two overarching goals: (1) to complete the protein parts list, with at least one protein product from each of the ~20,000 protein-coding genes along with sequence variants, splice variants, and post-translational modifications, with characterization of their functions;…

Read More

Meet Amir Dan Rubin, CEO of One Medical on June 6th at PMWC 2018 Michigan

Q: What are some of the biggest contributors to these challenges and how can we overcome them?

A: One of the underlying challenges driving the rising the cost of health care is that most of the health system’s stakeholders have few incentives, if not outright disincentives, to manage expenditures.

Read More

Interview with Steve Nelson, CEO, UnitedHealthcare Presenting at PMWC 2018 Michigan in June

Q: What’s the biggest misconception about UnitedHealthcare?

That we don’t care, that we’re just a health insurance company that pays or denies medical claims. In reality, helping people is at the core of what we do every day.

Read More

Emerging Technologies are Disrupting Healthcare | PMWC Michigan June 6-7

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Dan Rhodes from Strata Oncology

Q: What need is Strata Oncology addressing?

Despite substantial advances in precision oncology, the majority of advanced cancer patients still do not benefit from comprehensive tumor molecular profiling or precision therapy trials.

Read More

Interview with Lisa McLaughlin from Workit Health

Q: What need is Workit Health addressing?

Drug overdoses killed more Americans last year than were lost during the entire Vietnam War (69,000).

Read More

Interview with Olivier Elemento from Weill Cornell Medicine

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

I direct the Englander Institute for Precision Medicine, an Institute that focuses on using genomics and informatics to make medicine more individualized.

Read More

Interview with Dr. Dunnenberger from NorthShore University HealthSystem

Q: What patient population is NorthShore University HealthSystem serving and which services are you specializing in?

NorthShore is a four hospital community health system with over 100 outpatient medical offices.

Read More

How Artificial Intelligence (AI) Will Potentiate Individualized Medicine

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Jennifer Kloke from Ayasdi

Q: What need is Ayasdi addressing?

Ayasdi is pioneering the application of AI to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Q&A with Eric Topol, Executive Vice President, Scripps Research Institute

Dr. Eric Topol, voted by Modern Healthcare as the most influential physician executive in the United States, shared his thoughts on why people should own and control their own data.

Read More

CMS to Approve Coverage of NGS-based Cancer Testing | Big Pharma’s Response & The effect on PM

Why this is a Big Deal? As we know, private insurers follow suit once Medicare makes a decision such as this. This portends well for genetic testing to become routine standard of care for patients with advanced cancers.

Read More
University of Michigan

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Insights in the Clinic”.

Agenda highlights:

  • Two Track Program will showcase sessions on the latest advancements in precision medicine which include, but are not limited to: Transforming Big Data Into Actionable Information, Personalized Modeling of P4 Health, Emerging Technologies in Precision Medicine, The Economic and Socio-political Aspects of Precision Medicine, Precision Cancer Therapy, Session Scalable Infrastructure/Platforms to Power NGS for the Clinic, Genomic Data and Precision Health, Challenges and Barriers at the Community Setting, Opioid Precision Health, Pharmacogenomics Today and Tomorrow.
  • A lineup of 100+ highly regarded speakers featuring pioneering researchers and authorities across the healthcare and biotechnology sectors – browse select PMWC 2018 SV recorded talks
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
  • Track 2-PMWC 2018 Michigan Showcase, enable 15-minute company presentations on latest novel technologies.  See past PMWC Showcase presenters. Nominate here or apply to present here.

Confirmed thought leaders include:

Lee Hood

Lee Hood

Chief Science Officer, Providence Health

Eric Topol

Eric Topol

Chief Academic Officer, Scripps Health

Francis Collins

Francis Collins

Director of the National Institutes of Health (NIH)

Vicki L. Ellingrod

Vicki L. Ellingrod

Ass. Dir., Michigan Inst. for Clinical & Health Research

Goncalo Abecasis

Nancy Cox

Director, Vanderbilt Genetics Institute

Goncalo Abecasis

Pita Navarro

Head of Clinical Operations and Research, Athelas

Goncalo Abecasis

Goncalo Abecasis

Chair, Department of Biostatistics, UM

Jeffrey Leiden

Jeffrey Leiden

Chairman, President and CEO, Vertex

David Ginsburg

David Ginsburg

Prof., Human Genetics; Investigator, UM

Steve Nelson

Steve Nelson

Chief Executive Officer, UnitedHealthcare

Gil Omenn

Gil Omenn

Dir., Comput. Med. & Bioinformatics Center, UM

Eric Lefkofsky

Eric Lefkofsky

Founder and CEO, Tempus

Steven Leeder

Steven Leeder

Dir., Clin. Pharmacology Children’s Mercy Hospital,(CMH)

Ariella Shikanov

Ariella Shikanov

Assistant Professor, Biomedical Engineering, UM

Lawrence Corey

Lawrence Corey

Presi. & Dir. Emeritus, Fred Hutch Cancer Research Cent.

Amir Dan Rubin

Amir Dan Rubin

President and CEO, One Medical

Isaac (Zac) Kohane

Isaac (Zac) Kohane

Professor of Pediatrics, Harvard University

Sachin Kheterpal

Sachin Kheterpal

Associate Professor, Anesthesiology, UM

Matthias Kretzler

Matthias Kretzler

Professor, Nephrology & Internal Medicine, UM

Arul Chinnaiyan

Arul Chinnaiyan

Professor of Pathology, Medical Institute, UM

Registration: PMWC Conferences

Michigan June 6-7, 2018

First PMWC In Midwest
2 Track Speaker Lineup
Access to the exhibition
Breakfast & lunch refreshments
Award Reception

Having Trouble Registering? We accept all major credit cards. Select 'PayPal Check out' and press 'Pay with Debit or Credit Card'.
Click here or call (650)-961-8877 to contact the PMWC Team for Help or to ask about the academic rate.

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!